Managing GIST in the imatinib era: Optimization of adjuvant therapy

Jonathan C. Trent, Meenakshi P. Subramanian

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


We reviewed studies evaluating the clinical benefits of 1 year or more of adjuvant imatinib therapy in patients with gastrointestinal stromal tumor (GIST). Data from the Scandinavian Sarcoma Group (SSG) XVIII/AIO Phase III trial of 1 year versus 3 years of adjuvant imatinib support the use of 3 years as standard of care in patients who are at high risk for GIST recurrence following resection. Although adjuvant imatinib therapy prolonged recurrence-free survival in the evaluated trials, overall survival was not significantly increased except in the SSG XVIII/AIO trial. The optimal duration of therapy, and whether high-risk patients should use adjuvant imatinib continuously, remains unknown. The importance of risk assessment, risk stratification and GIST genotype in patient selection is also discussed.

Original languageEnglish (US)
Pages (from-to)1445-1459
Number of pages15
JournalExpert review of anticancer therapy
Issue number12
StatePublished - Dec 1 2014
Externally publishedYes


  • adjuvant drug therapy
  • gastrointestinal stromal tumor
  • GIST
  • imatinib mesylate
  • mutational analysis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'Managing GIST in the imatinib era: Optimization of adjuvant therapy'. Together they form a unique fingerprint.

Cite this